C S An, L M Petrovic, I Reyter, T Tolmachoff, L D Ferrell, S N Thung, S A Geller, A M Marchevsky – 30 December 2003 – Liver cell dysplasia (LCD) is considered a preneoplastic lesion, whose characterization and differentiation from hepatocellular carcinoma (HCC) and from the reactive changes seen in cirrhosis has been controversial. We studied 12 cases of LCD (large cell type) with image analysis techniques (IA) and compared the findings with those of HCC (n = 40), and a spectrum of non‐neoplastic hepatic lesions including normal liver and cirrhosis (n = 49).

T F Kresina – 30 December 2003

M J Sharrard, M Durkie, M S Tanner – 30 December 2003

A M Larson, G C Chan, C F Wartelle, J P McVicar, R L Carithers, G M Hamill, K V Kowdley – 30 December 2003 – There is controversy about the frequency of and risk factors for infectious complications of percutaneous liver biopsy in liver transplant recipients. The aim of this study was to identify the incidence and nature of complications associated with liver biopsy after orthotopic liver transplantation (OLT), with particular emphasis on infection.

C A Camargo, J F Madden, W Gao, R S Selvan, P Clavien – 30 December 2003 – Interleukin‐6 (IL‐6) is an acute reactant cytokine with anti‐inflammatory properties, which has been found to prevent injury in a model of acute hepatitis in mice through downregulation of tumor necrosis factor α (TNF‐α); to correlate inversely with markers of hepatocellular injury in patients with liver ischemia; and to initiate liver regeneration in mice. In this study, we investigated the role of IL‐6 in rodent models of hepatic warm ischemia/reperfusion (WI/Rp) injury.

L Meng, H Reyes, M Axelson, J Palma, I Hernandez, J Ribalta, J Sjovall – 30 December 2003 – The concentrations in serum of sulfated metabolites of progesterone are known to be elevated in patients with intrahepatic cholestasis of pregnancy (ICP). The profiles of these metabolites and conjugated bile acids were analyzed in serum from 11 patients with ICP before and during administration of ursodeoxycholic acid (UDCA) (8 patients) or placebo (3 patients).

T Tordjmann, B Berthon, B Lardeux, A Moreau, E Jacquemin, L Combettes, G Feldmann, M Claret – 30 December 2003 – Morphological and functional heterogeneity of hepatocytes according to their position in the liver lobule has been known for many years. The digitonin‐collagenase perfusion technique is widely used to study hepatocyte heterogeneity and has yielded reliable data. However, with this procedure, periportal (PP) or perivenous (PV) hepatocytes are isolated from different livers, allowing only comparison between cell populations issued from two separate animals.

M C Shuhart, M P Bronner, D R Gretch, L V Thomassen, C F Wartelle, H Tateyama, S S Emerson, J D Perkins, R L Carithers – 30 December 2003 – Hepatitis frequently recurs after liver transplantation for hepatitis C. However, the histological progression of disease, predictors of recurrence and disease severity, and patient survival remain uncertain. Fifty‐five patients with cirrhosis caused by chronic hepatitis C underwent liver transplantation between January 1990 and December 1993.

L B Seeff – 30 December 2003 – Approximately 85% of persons with acute hepatitis C develop chronic hepatitis as determined by persistently abnormal serum enzymes and/or viremia (hepatitis C virus [HCV] RNA). Both the acute and chronic illnesses are predominantly asymptomatic. For this reason and because the chronic illness runs an extremely protracted course, it has been difficult to accurately define the frequency and rate of progression to symptomatic or end‐stage liver disease, specifically cirrhosis and hepatocellular carcinoma (HCC). Three evaluation strategies have been used.

G L Davis, J Y Lau – 30 December 2003 – Alpha interferon is the only drug that has been shown to be effective in the treatment of chronic hepatitis C, but only half of patients respond, either transiently or permanently. Pretreatment features that are associated with a greater likelihood of response to short courses of interferon include low hepatitis C virus (HCV) RNA levels, viral genotypes 2 or 3, and the absence of fibrosis or cirrhosis on liver biopsy. Each of these features is more predictive of sustained response (SR) than the end‐of‐treatment response (ETR).